101
|
Qin S, Kim TY, Lim H, Ryoo BY, Zhou D, Zhao C, Becker A, Cheng AL. Final data from a phase Ib trial of tepotinib in Asian patients with advanced hepatocellular carcinoma (HCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.085] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
102
|
Qin S, Jie Z. Early characteristics of breast neoplasms on contrast-enhanced ultrasonography and its clinical value. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx364.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
103
|
Vogel A, Qin S, Kudo M, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López López C, Sung M, Dutcus C, Kraljevic S, Tamai T, Grunow N, Meier G, Breder V. Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
104
|
Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, Palileo-Villaneuva L, Lopez-Jaramillo P, Karaye K, Yusoff K, Orlandini A, Sliwa K, Mondo C, Lanas F, Prabhakaran D, Badr A, Elmaghawry M, Damasceno A, Tibazarwa K, Belley-Cote E, Balasubramanian K, Islam S, Yacoub MH, Huffman MD, Harkness K, Grinvalds A, McKelvie R, Bangdiwala SI, Yusuf S, Campos R, Chacón C, Cursack G, Diez F, Escobar C, Garcia C, Vilamajo OG, Hominal M, Ingaramo A, Kucharczuk G, Pelliza M, Rojas A, Villani A, Zapata G, Bourke P, Lanas F, Nahuelpan L, Olivares C, Riquelme R, Ai F, Bai X, Chen X, Chen Y, Gao M, Ge C, He Y, Huang W, Jiang H, Liang T, Liang X, Liao Y, Liu S, Luo Y, Lu L, Qin S, Tan G, Tan H, Wang T, Wang X, Wei F, Xiao F, Zhang B, Zheng T, Mendoza JA, Anaya MB, Gomez E, de Salazar DM, Quiroz F, Rodríguez M, Sotomayor MS, Navas AT, León MB, Montalvo LF, Jaramillo ML, Patiño EP, Perugachi C, Trujillo Cruz F, Elmaghawry M, Wagdy K, Bhardwaj A, Chaturvedi V, Gokhale GK, Gupta R, Honnutagi R, Joshi P, Ladhani S, Negi P, Roy A, Reddy N, Abdullah A, Hassan MA, Balasinga M, Kasim S, Tan W, Yusoff K, Damasceno A, Banze R, Calua E, Novela C, Chemane J, Akintunde A, Ansa V, Gbadamosi H, Karaye K, Mbakwem A, Mohammed S, Nwafor E, Ojji D, Olunuga T, Sa'idu BOH, Umuerri E, Alcaraz J, Palileo-Villanueva L, Palomares E, Timonera MR, Badr A, Alghamdi S, Alhabib K, Almasood A, Alsaif S, Elasfar A, Ghabashi A, Mimish L, Bester F, Kelbe D, Klug E, Sliwa K, Tibarzawa K, Abdalla O, Dimitri M, Mustafa H, Osman O, Saad A, Mondo C. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. LANCET GLOBAL HEALTH 2017; 5:e665-e672. [DOI: 10.1016/s2214-109x(17)30196-1] [Citation(s) in RCA: 174] [Impact Index Per Article: 24.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Revised: 04/10/2017] [Accepted: 04/26/2017] [Indexed: 12/13/2022]
|
105
|
Basak C, Nashiro K, O’Connell M, Qin S. PLAYING FOR KEEPS: EFFECTS OF VIDEO GAME TRAINING ON NEURAL AND COGNITIVE PLASTICITY IN OLDER ADULTS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.5022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
106
|
Qin S, Xia Y, Miao Y, Qiao C, Xu W, Li J. MYD88
MUTATIONS PREDICT UNFAVORABLE PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH MUTATED IGHV
GENE. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
107
|
Bekaii-Saab T, Goldstein D, Li C, Okusaka T, O’Neil B, Reni M, Tabernero J, Qin S, Van Cutsem E, Borodyansky L, Li C. CanStem111P trial: A phase III study of napabucasin plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx261.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
108
|
Qin S, Fan L, Xia Y, Liang J, Xu W, Li J. DEFINITION OF DISEASE-PROGRESSION RISK STRATIFICATION IN UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA USING COMBINED CLINICAL, MOLECULAR AND VIROLOGICAL VARIABLES. Hematol Oncol 2017. [DOI: 10.1002/hon.2439_145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
109
|
Peng C, Gu X, Gao X, Li X, Qin S, Ma M, Cui M, Xie M, Bai Y. PV-0508: Prognostic significance of PD-L1 expression in patients with head and neck squamous cell carcinoma. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30948-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
110
|
Xiao G, Zhang J, Sun X, Qin S, Zhang B, Liu D, Liu J, Ren H. Abstract P4-07-11: MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-07-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Increasing studies showed that MicroRNAs (miRNAs)participate in the carcinogenesis and progression of breast cancer, but the specific mechanism of miRNAs in breast cancer needs to be furtherexplored. in this study, wefound that miR-367a was significantly up-regulated in breast cancer tissue samples and cell lines, compared to paired normal tumor-adjacent samples and MCF-10A. meanwhile, Kaplan–Meier analysis demonstrated high miR-367a expression was evidently correlated with poor prognostic features of breast cancer. overexpression of miR-367a remarkably promoted proliferation, cell cycle,inhibited apoptosis ratios and stem-like capacity of breast cancer cells in vitro, whilesilencing the expression of miR-367a dramaticallyreversed these cellular events .in addition,In vivo studies showed that knockdown of miR-367a inhibited tumor growth of breast cancer ,moreover, F-box and WD repeat domain-containing 7 (FBXW7) was identified as a direct target genes of miR-367a, as miR-367a directly bound to the 3'untranslated region of FBXW7 . Notably, alterations of FBXW7 levels abrogated the effects of miR-367a on breast cancer cell proliferation, cell cycle, apoptosis and stemness potential. In conclusion,evidence from this study demonstrated that miR-367amay serve as a novel prognostic indicator for breast cancer patients andexerts tumor promotion,at least in part, by inhibiting FBXW7.
Key words: miR-367a, FBXW7, breast cancer, tumor growth, stem-like capacity.
Citation Format: Xiao G, Zhang J, Sun X, Qin S, Zhang B, Liu D, Liu J, Ren H. MicroRNA-367a promotes tumor growth and stemness potential by targeting FBXW7 in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-07-11.
Collapse
|
111
|
Qin S, Tian G, Zhang K, Ding X, Bai S, Wang J, Jia G, Zeng Q. Influence of dietary rapeseed meal levels on growth performance, organ health and standardized ileal amino acid digestibility in meat ducks from 15 to 35 days of age. J Anim Physiol Anim Nutr (Berl) 2017; 101:1297-1306. [PMID: 28133825 DOI: 10.1111/jpn.12649] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Accepted: 11/03/2016] [Indexed: 11/27/2022]
Abstract
This study was conducted to investigate the effects of dietary rapeseed meal (RSM) inclusion levels on growth performance, organ health and standardized ileal amino acid digestibility (SIAAD) in meat ducks from 15 to 35 days of age. Six hundred and eighty 15-days-old ducks were randomly allotted to five treatments based on body weight. Five isonitrogenous and isoenergetic diets were formulated on a digestible amino acid basis by replacing 0% (the control), 25%, 50%, 75% and 100% (based on fresh) of protein from soya bean meal (SBM) with protein from RSM. The corresponding levels of RSM in experimental diets were 0%, 6.66%, 13.32%, 19.98% and 26.64% respectively. With increasing dietary RSM levels, body weight (BW) and average daily gain (ADG) linearly decreased (p < 0.001), whereas feed-to-gain ratio (F: G) linearly increased (p = 0.0078). Ducks fed the diets with 13.32% or more RSM had significantly lower (p < 0.05) BW, ADG and ADFI, or higher F: G than ducks fed the control diet. The maximum limit of dietary RSM supplementation was estimated to range from 4.27% to maximize ADG for 15 to 35 days to 11.69% to maintain feed intake for 15 to 35 days on the basis of a broken-line model. At day35, the 4th primary wing feather length and SIAAD (except for Met, Thr and Val) linearly decreased (p < 0.001), and the thyroid glands weight (% of BW) linearly increased (p < 0.05) with increasing dietary RSM levels. Ducks fed the RSM inclusion diets had significantly lower (p < 0.0001) serum aspartate aminotransferase (AST) and alanine transaminase (ALT) activities than ducks fed the control diet. These results suggested that the maximum limit of dietary RSM containing 7.57 μmol/g glucosinolates was estimated to be 4.27% to avoid growth reduction.
Collapse
|
112
|
Qin S, Xu J, Wang L, Cheng Y, Liu T, Chen J, Liu J, Li J. 169P First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type metastatic colorectal cancer: The open-label, randomized, phase 3 TAILOR trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw581.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
113
|
Chen F, Zhu L, Qiu H, Qin S. Selenium-enrichedSaccharomyces cerevisiaeimproves growth, antioxidant status and selenoprotein gene expression in Arbor Acres broilers. J Anim Physiol Anim Nutr (Berl) 2016; 101:259-266. [DOI: 10.1111/jpn.12571] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 06/17/2016] [Indexed: 11/29/2022]
|
114
|
Chen T, Guo ZP, Fu LX, Cao N, Qin S. Anti-TWEAK monoclonal antibodies reduce vascular damage and leucocyte infiltration in a mouse model of cutaneous reverse passive Arthus reaction. Clin Exp Dermatol 2016; 41:871-877. [PMID: 27753135 DOI: 10.1111/ced.12912] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/19/2015] [Indexed: 02/05/2023]
|
115
|
Qin S, Xu J, Wang L, Cheng Y, Liu T, Chen J, Eggleton S, Liu J, Li J. Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 ± cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.75] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
116
|
Feng Z, Tao C, Yu G, Qin S, Zhu J, Ma C, Yin Y, Li D. Comparison of the Biology Optimization and Physical Optimization for Cervical Carcinoma. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
117
|
Bang YJ, Boku N, Chin K, Lee KW, Park S, Qin S, Rha S, Shen L, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Xu R. gastrointestinal tumours, non-colorectal Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy: Phase III GOLD study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.16] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
118
|
Huang P, Li D, Kapp D, Li H, Chen J, Ma C, Yu G, Qin S, Yin Y, Yang Y, Xing L. Adjusted Dose and the Relation to Radiation-Induced Liver Disease During Liver 3-Dimensional Conformal Radiation Therapy. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.2202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
119
|
Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross P, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G. Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.19] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
120
|
Qin S, Gao X, Li H, Liu C, Hou D, Nian W, Li X. Endorectal Epinephrine Suspension May Protect Against Radiation Proctitis During Radiation Therapy for Pelvic Tumor. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
121
|
Kim T, Shen L, Xu J, Sriuranpong V, Pan H, Xu R, Han SW, Liu T, Park Y, Shir C, Bai Y, Bi F, Ahn J, Qin S, Li Q, Wu C, Zhou F, Ma D, Srimuninnimit V, Li J. TERRA: a randomized, double-blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw370.14] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
122
|
Huang P, Li H, Chen J, Ma C, Gang Y, Qin S, Yin Y, Li D. SU-G-206-16: Investigation of Dosimetric Consequence Via Cone-Beam CT Based Dose Reconstruction in Hepatocellular Carcinoma Radiotherapy. Med Phys 2016. [DOI: 10.1118/1.4956957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
123
|
Qin S, Xu J, Wang L, Cheng Y, Liu T, Chen J, Eggleton S, Liu J, Li J. LBA-05 First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw237.05] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
124
|
Feng Z, Tao C, Zhu J, Yu G, Qin S, Yin Y, Li D. SU-F-T-257: Comparison Study of the Biological and Physical Optimization for Cervical Carcinoma. Med Phys 2016. [DOI: 10.1118/1.4956397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
125
|
Huang P, Li H, Chen J, Ma C, Gang Y, Qin S, Yin Y, Li D. SU-F-J-221: Adjusted Dose and Its Relation to Radiation Induced Liver Disease During Hepatocellular Carcinoma Radiotherapy. Med Phys 2016. [DOI: 10.1118/1.4956129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|